Development of a reminiscence therapy online platform with machine learning to increase engagement with people living with dementia and their care partners

开发具有机器学习功能的回忆疗法在线平台，以增加与痴呆症患者及其护理伙伴的互动

• 批准号: 10227234
• 负责人: Lisbeth Sanders
• 金额: $ 110.76万
• 依托单位: LIFEBIO INC
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10227234
• 关键词: Affect; Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; American; Artificial Intelligence; Assisted Living Facilities; Behavioral Symptoms; Books; Caregivers; Caring; Cause of Death; Cessation of life; Cognition; Communication; Consumption; Data; Dementia; Dependence; Development; Disease; Elderly; Elements; Empathy; Environment; Evaluation; Event; Exercise Therapy; Family Caregiver; Family member; Feedback; Financial Hardship; Focus Groups; Generations; Health Personnel; Impaired cognition; Individual; Institutes; Internet; Intervention; Interview; Knowledge; Life; Machine Learning; Memory; Mental Health; Modification; Monitor; Moods; Music; Nature; Nursing Homes; Oral; Outcome; Output; Participant; Patients; Persons; Phase; Pilot Projects; Procedures; Process; Qualitative Evaluations; Quality of life; Quantitative Evaluations; Reporting; Research; Residential Treatment; Side; Small Business Innovation Research Grant; Source; Speech; Surveys; Symptoms; System; Techniques; Testing; Text; Time; Training; United States Centers for Medicare and Medicaid Services; Work; acceptability and feasibility; aged; base; caregiving; dementia care; depressive symptoms; design; effective intervention; experience; improved; interactive tool; life history; long term memory; novel; person centered; physical conditioning; point of care; programs; prototype; psychological symptom; symptomatology; tool; usability; user-friendly; web site

PROJECT SUMMARY Almost 6 million Americans are living with Alzheimer’s disease (AD) or AD-related dementias, and the number of affected individuals is rapidly growing. Symptoms include impaired cognition, resulting in difficulty in performing daily activities and consequent functional dependence on others. The progressive nature of AD and ADRD can result in increasing degrees of care required from professional and family caregivers. Non- pharmacologic interventions positively influence cognition, mood, and other behavioral and psychological symptoms of dementia, and one well-established intervention, life story work (the use of written and oral life histories), serves as an effective technique that can elicit conversation and memories in those with AD and ADRD. However, generating useful life story materials is a time-consuming task for caregivers. To overcome this barrier, LifeBio Inc. is developing a reminiscence therapy platform —LifeBio MemoryTM— with a novel machine-learning-based application that converts speech to text and generates life stories to serve as an interactive tool to cultivate communication between people living with dementia and their family and caregivers. The LifeBio MemoryTM platform application will elicit and store individuals’ stories, photos, and videos and ultimately deliver personalized, point-of-care reminiscence therapy exercises for patients. In preliminary work supporting this Direct-to-Phase II proposal, LifeBio Inc. partnered with the Benjamin Rose Institute on Aging to conduct a pilot study in nursing homes, which showed a significant decrease in depressive symptoms among participants in LifeBio Inc.’s intervention and revealed that the majority of participants considered knowledge of their life story to be important for caregivers, while caregivers also reported positive experiences in relation to the impact of the intervention on caregiving. In this project we will: 1) Develop prototype enhancements of the existing LifeBio program and conduct focus group evaluations of these prototypes with 12 existing or former LifeBio users, 20 dementia care professionals familiar with LifeBio and 6 older adults with early-stage dementia to help maintain person-centered practices throughout the research process; 2) Finalize the LifeBio Memory product, which will include the development of a system to automatically record and process individuals’ life stories. 3) Conduct a full-scale fidelity trial of the complete package with 40 care professionals and 160 dementia care dyads across within an assisted living setting. The product of this Direct-to-Phase II proposal, LifeBio Memory™, will be a novel, scalable, and easily implemented solution through which caregivers and healthcare providers can offer person-centered care to people living with AD and AD-related dementias.

项目概要 近 600 万美国人患有阿尔茨海默病 (AD) 或与 AD 相关的痴呆症，而且这个数字 受影响个体的症状正在迅速增加，其中包括认知障碍，导致行动困难。 进行日常活动以及由此产生的对他人的功能依赖 AD 的渐进性和 ADRD 可能会导致专业和家庭护理人员需要越来越多的护理。 药物干预对认知、情绪和其他行为和心理产生积极影响 痴呆症的症状，以及一种行之有效的干预措施，生活故事作品（使用书面和口头生活 历史），作为一种有效的技术，可以引发 AD 和 AD 患者的对话和记忆 然而，对于护理人员来说，生成有用的生活故事材料是一项耗时的任务。 为了克服这一障碍，LifeBio Inc. 正在开发一种回忆治疗平台——LifeBio MemoryTM——采用一种新颖的方法 基于机器学习的应用程序，可将语音转换为文本并生成生活故事作为 互动工具，用于培养痴呆症患者与其家人和护理人员之间的沟通。 LifeBio MemoryTM 平台应用程序将引出并存储个人的故事、照片和视频， 在前期工作中，最终为患者提供个性化的护理点回忆治疗练习。 为了支持这项直接进入第二阶段的提案，LifeBio Inc. 与本杰明·罗斯老龄化研究所合作， 在疗养院进行一项试点研究，结果显示，老年人的抑郁症状显着减少 参与 LifeBio Inc. 干预的参与者并透露，大多数参与者认为了解 他们的生活故事对护理人员来说很重要，而护理人员也报告了与以下方面有关的积极经历 干预对护理的影响 在这个项目中，我们将： 1) 开发原型增强功能。 现有的 LifeBio 计划，并对这些原型进行焦点小组评估，其中 12 名现有或前任 LifeBio 用户、20 名熟悉 LifeBio 的痴呆症护理专业人员和 6 名患有早期痴呆症的老年人 帮助在整个研究过程中保持以人为本的实践；2) 最终确定 LifeBio 记忆 产品，其中将包括开发一个自动记录和处理个人生活的系统 3) 对 40 名护理专业人员和 160 名痴呆症患者进行全面的保真度试验。 LifeBio 是这项直接进入第二阶段提案的产品。 Memory™ 将是一种新颖、可扩展且易于实施的解决方案，护理人员和医疗保健人员可以通过它 医疗服务提供者可以为 AD 患者和 AD 相关痴呆症患者提供以人为本的护理。